Dissolution Similarity Requirements: How Similar or Dissimilar Are the Global Regulatory Expectations?

被引:145
作者
Diaz, Dorys Argelia [1 ]
Colgan, Stephen T. [1 ]
Langer, Connie S. [1 ]
Bandi, Nagesh T. [2 ]
Likar, Michael D. [3 ]
Van Alstine, Leslie [3 ]
机构
[1] Pfizer Inc, Global Chem & Mfg Controls, Worldwide Res & Dev, Groton, CT 06340 USA
[2] Pfizer Inc, Global Chem & Mfg Controls, Worldwide Res & Dev, Peapack, NJ 07977 USA
[3] Pfizer Inc, Analyt Res & Dev, Worldwide Res & Dev, Groton, CT 06340 USA
关键词
chemistry manufacturing and controls (CMC); comparative dissolution; f(2); global; regulatory; similarity factor; STATISTICS; DRUG;
D O I
10.1208/s12248-015-9830-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The objective of this article is to compare and contrast the international expectations associated with the model-independent similarity factor approach to comparing dissolution profiles. This comparison highlights globally divergent regulatory requirements to meet local dissolution similarity requirements. In effect, experiments customized to meet the current international regulatory expectations for dissolution and drug release unnecessarily increase manufacturing costs, hinder science and risk-based approaches, increase collective regulatory burden, reduce continuous improvement and innovation, and potentially delay patient access to urgently needed medication. Comparative assessment of regulatory differences in applying dissolution to demonstrate product similarity is crucial to reduce non-scientifically justified experiments and foster collaborative harmonization among global regulatory health authorities and the pharmaceutical industry.
引用
收藏
页码:15 / 22
页数:8
相关论文
共 24 条
[1]  
[Anonymous], 1997, Dissolution Testing of Immediate Release Solid Oral Dosage Forms
[2]  
Guidance for Industry
[3]  
[Anonymous], 1995, Immediate Release Solid Oral Dosage Forms: Scale-Up and Postapproval Changes: Chemistry,Manufacturing, and Controls
[4]  
In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation.
[5]  
Central Drugs Standard Control Organization, 2005, GUID BIOAV BIOEQ STU
[6]  
China FDA. Center for Drug Evaluation, 2015, TECHN GUID IN PRESS
[7]  
COFEPRIS. Secretaria de Salud, 2013, NOM177SSA12013 COFEP
[8]  
Dekker T, 2011, WHO PREQUALIFICATION
[9]  
Department of Health Therapeutic Goods Administration, 2013, MIN VAR REG PRESCR M
[10]  
Drug Control Division Thailand, 2009, GUID COND BIOAV BIOE